Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zevra Therapeutics Inc ZVRA

Healthcare
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered... see more

Recent & Breaking News (NDAQ:ZVRA)

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA(TM) (arimoclomol) for Treatment of Niemann-Pick Disease Type C

GlobeNewswire 1 day ago

Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates

GlobeNewswire 10 days ago

Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting

GlobeNewswire 11 days ago

Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13

GlobeNewswire November 6, 2024

Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024

GlobeNewswire October 31, 2024

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

GlobeNewswire October 10, 2024

NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign to Highlight Critical Importance of Prompt, Accurate Blood Ammonia Testing for Diagnosing Urea Cycle Disorders

GlobeNewswire October 9, 2024

Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024

GlobeNewswire September 24, 2024

Zevra Therapeutics' MIPLYFFA(TM) (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C

GlobeNewswire September 20, 2024

Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

GlobeNewswire September 6, 2024

Zevra Therapeutics to Participate at Upcoming Investor Conferences

GlobeNewswire August 29, 2024

Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights

GlobeNewswire August 13, 2024

Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock

GlobeNewswire August 9, 2024

Zevra Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire August 8, 2024

Zevra Therapeutics to Present at Canaccord Genuity's 44th Annual Growth Conference

GlobeNewswire August 7, 2024

FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C

GlobeNewswire August 2, 2024

Zevra Therapeutics to Report Second Quarter 2024 Financial Results

GlobeNewswire July 30, 2024

Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

GlobeNewswire July 9, 2024

Zevra Therapeutics Expands Executive Leadership Team

GlobeNewswire June 25, 2024

Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders

GlobeNewswire June 18, 2024